"Deoxycytidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE.
| Descriptor ID |
D003841
|
| MeSH Number(s) |
D03.383.742.680.245.500 D13.570.230.329 D13.570.685.245.500
|
| Concept/Terms |
Deoxycytidine- Deoxycytidine
- Cytosine Deoxyribonucleoside
- Deoxyribonucleoside, Cytosine
- Cytosine Deoxyriboside
- Deoxyriboside, Cytosine
|
Below are MeSH descriptors whose meaning is more general than "Deoxycytidine".
Below are MeSH descriptors whose meaning is more specific than "Deoxycytidine".
This graph shows the total number of publications written about "Deoxycytidine" by people in this website by year, and whether "Deoxycytidine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2003 | 2 | 0 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 2 | 2 | 4 |
| 2009 | 1 | 2 | 3 |
| 2010 | 1 | 0 | 1 |
| 2013 | 1 | 3 | 4 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 2 | 3 |
| 2016 | 0 | 2 | 2 |
| 2017 | 3 | 0 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Deoxycytidine" by people in Profiles.
-
Treatment of locally advanced pancreatic cancer using localized trans-arterial micro perfusion of gemcitabine: combined analysis of RR1 and RR2. Oncologist. 2024 Aug 05; 29(8):690-698.
-
Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression. Gastroenterology. 2021 11; 161(5):1584-1600.
-
Treatment and Visualization of Pancreatic Ductal Adenocarcinoma through Actively Targeted Copper 64 Nanoparticles. Radiol Imaging Cancer. 2021 03; 3(2):e219005.
-
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int. 2021 05; 127(5):528-537.
-
Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study. Br J Surg. 2020 08; 107(9):1171-1182.
-
Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. Int J Nanomedicine. 2020; 15:991-1003.
-
ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin a3ß1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells. Gastroenterology. 2020 02; 158(3):679-692.e1.
-
A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer. J Pharmacol Exp Ther. 2019 09; 370(3):894-901.
-
Insights into gemcitabine resistance and the potential for therapeutic monitoring. Metabolomics. 2018 11 27; 14(12):156.
-
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018 05 08; 319(18):1880-1888.